Designer benzodiazepines gidazepam and desalkygidazepam (bromonordiazepam): what do we know?

Maskell, P. D. , Wilson, G. and Manchester, K. R. (2023) Designer benzodiazepines gidazepam and desalkygidazepam (bromonordiazepam): what do we know? Journal of Analytical Toxicology, 47(4), pp. 324-331. (doi: 10.1093/jat/bkad004) (PMID:36695345)

Abstract

Designer benzodiazepines are one of the primary new psychoactive substances (NPS) threats around the world, being found in large numbers in post-mortem, driving under the influence of drugs (DUID) and drug facilitated sexual assault (DFSA) cases. Even though when compared to many other NPS types, such as opioids and cathinones, there are relatively few designer benzodiazepines being monitored. Recently a new NPS benzodiazepine has been reported in Europe, the USA and Canada, desalkygidazepam, also known as bromonordiazepam. This substance is a metabolite of the pro-drug gidazepam, a drug licenced for use in Ukraine and Russia under the name Gidazepam IC®. In the paper we review what is currently known about the use, pharmacology and analytical detection of gidazepam, its metabolite desalkygidazepam, and their other possible metabolites.

• Item Type: Articles
• Status: Published
• Refereed: Yes
• Glasgow Author(s) Enlighten ID: Maskell, Peter
• Authors: Maskell, P. D., Wilson, G., and Manchester, K. R.
• College/School: College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing
• Journal Name: Journal of Analytical Toxicology
• Publisher: Oxford University Press
• ISSN: 0146-4760
• ISSN (Online): 1945-2403
• Published Online: 25 January 2023
• Copyright Holders: Copyright © 2023 The Authors
• First Published: First published in Journal of Analytical Toxicology 47(4):324–331
• Publisher Policy: Reproduced in accordance with the publisher copyright policy